{"nctId":"NCT00528424","briefTitle":"AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease","startDateStruct":{"date":"2007-12","type":"ACTUAL"},"conditions":["Advanced Dupuytren's Disease"],"count":286,"armGroups":[{"label":"AA4500 0.58 mg","type":"EXPERIMENTAL","interventionNames":["Biological: AA4500"]}],"interventions":[{"name":"AA4500","otherNames":["XIAFLEX®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with a diagnosis of advanced Dupuytren's disease, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100° for MP (80° for PIP) joints, caused by a palpable cord.\n* Had a positive \"table top test,\" defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.\n* Were naïve to AA4500 treatment or had received only one or two injections of AA4500 for the treatment of advanced Dupuytren's disease in AUX-CC-857 ((NCT00528606).\n* Were judged to be in good health.\n* Must have participated in protocol AUX-CC-857 (NCT00528606).\n\nExclusion Criteria:\n\n* Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.\n* Had received treatment for advanced Dupuytren's disease within 90 days of enrollment on the joint selected for the initial injection of AA4500, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon.\n* Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Reduction in Contracture to 5° or Less","description":"Successfully treated or clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Improvement After the Last Injection","description":"Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction From Baseline Contracture After the Last Injection","description":"Percent change in degree of contracture in non-primary joints measured as 100 \\* (baseline contracture - last available post-injection contracture)/baseline contracture.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.8","spread":"39.00"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Range of Motion After the Last Injection","description":"Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion - baseline range of motion","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":"20.83"}]}]}]},{"type":"SECONDARY","title":"Time to Reach Clinical Success","description":"Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Success After the First Injection","description":"Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Improvement After the First Injection","description":"Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction From Baseline Contracture After the First Injection","description":"Percent change in degree of contracture in non-primary joints measured as 100 \\* (baseline contracture - last available post-injection contracture)/baseline contracture.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.9","spread":"38.64"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Range of Motion After the First Injection","description":"Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion - baseline range of motion","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":"19.46"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":286},"commonTop":["Oedema peripheral","Contusion","Pain in extremity","Injection site haemorrhage","Injection site pain"]}}}